Rabies Clinical Trial
Official title:
A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China
This study investigates the safety and immunogenicity (non-inferiority) of a Purified Chick Embryo Cell Vaccine (PCECV) administered in two different schedules (conventional versus abbreviated schedule) in healthy adults 18 to 50 years of age in China
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03961555 -
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
|
Phase 2 | |
Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
Active, not recruiting |
NCT05667974 -
A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-dried
|
Phase 3 | |
Completed |
NCT01641315 -
Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
|
N/A | |
Completed |
NCT02238756 -
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT01930357 -
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
|
Phase 2 | |
Completed |
NCT01680016 -
A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
|
Phase 3 | |
Completed |
NCT04019444 -
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02729168 -
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
|
N/A | |
Completed |
NCT02241135 -
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
|
Phase 1 | |
Completed |
NCT01388985 -
Simplifying the Rabies Pre-exposure Vaccination
|
Phase 3 | |
Completed |
NCT04829630 -
Immunity Persistence After Abridged Intradermal Rabies PEP
|
N/A | |
Completed |
NCT03713086 -
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT05350735 -
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
|
N/A | |
Active, not recruiting |
NCT06132789 -
A Clinical Trial of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried in a Population Aged 10-60 Years
|
Phase 1 | |
Completed |
NCT02281396 -
The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans
|
Phase 1 | |
Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
Completed |
NCT05547815 -
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
|
Phase 4 | |
Completed |
NCT02564471 -
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
|
Phase 4 | |
Unknown status |
NCT01173302 -
Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose
|
Phase 4 |